The global pharmaceutical contract manufacturing market was valued at over $58 billion in 2015 and is expected to surpass $82 billion by 2020, says Technavio.
Technavio’s cardiovascular and metabolic disorders portfolio has announced its latest market research report on pharmaceutical contract manufacturing for the forecast period, 2016-2020. This market analysis discusses the major drivers and key emerging trends that will influence the growth of the global pharmaceutical contract manufacturing market during the forecast period. Some of the top vendors listed in this industry analysis include Catalent, Lonza, and Pfizer CentreOne.
In terms of geographical analysis, the Americas will be the largest region in the global market, reaching revenues of around $31 billion by 2020. The US, Brazil, and Mexico will emerge as the key revenue-generators.
“The advancement in healthcare and biotechnology will increase the use of next-generation biologics in developing and developed countries. These are novel and improved treatments that are changing the healthcare landscape. The different types of next-generations biologics include ADCs, regenerative medicine, antibody fragments and antibody-like proteins (ALPs), oral insulins, recombinant coagulation factors with extended half-lives, and growth hormones,” says Sapna Jha, a lead analyst at Technavio for research on cardiovascular and metabolic disorders.
Click here to request a free sample of this report
This new industry research report from Technavio analyzes some of the key drivers and trends responsible for the growth of this market and its sub-segments.
Increased focus on core competence
The pharma companies are outsourcing partial or all their manufacturing activities to other contract manufacturers to concentrate on innovation and brand building. The primary role of contract manufacturers is to increase the profitability of sourcing companies, through economies of scale, cheap labor, and land while the sourcing companies focus on addressing the market challenges.
High number of US FDA-approved manufacturing facilities in emerging countries
The pharma companies are sanctioning contracts to partnering firms that have US FDA-approved plants, skilled workforce, and low operating costs. India has more than 100 US FDA approved manufacturing facilities, is one of the most preferred locations for outsourcing manufacturing services and encouraging pharma companies to partner with Indian contract manufacturing vendors. The introduction of the WTO TRIPS-mandated product patents is increasing the number of outsourcing contracts to various developed markets.
Shorter time-to-market
The growth in urbanization, rise in income, and increasing health awareness is fuelling the growth in the pharmaceutical industry. The industry is making huge investments for intensive technology setup furnished with high-tech equipment to improve the production process with higher efficiency and helps the drug supply to meet the increased demand while maintaining quality standards. The pharma companies are focusing on intensive R&D and identifying the shortest possible route for the drugs to reach people in final dosage form from the lab.
Other prominent vendors identified in this report are Abbott, Aenova, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, BERLIN-CHEMIE, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Daiichi Sankyo, Dr. Reddy’s Laboratories, Eli Lilly, Emcure Pharmaceuticals, Eurofarma Laboratories, Fareva, Gedeon Richter, Gilead Sciences, GlaxoSmithKline (GSK),Hospira, Impax Laboratories, Intas Pharmaceuticals, Janssen Pharmaceuticals, Lupin, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Natco Pharma, Nexus Pharmaceuticals, Novo Nordisk, Orchid Chemicals & Pharmaceuticals, Par Pharmaceutical, Parenteral Drugs India, Patheon, Piramal, Roche Holding, Sanofi, Synthon, Teva Pharmaceuticals, Valeant Pharmaceuticals, Zentiva, Zhejiang Huahai Pharmaceutical, and Zydus Cadila.
This research report includes an in-depth analysis, market shares, and sizes of the sub-segments and geography. It provides a comprehensive analysis of the key companies, including their market shares, business overview, and key financials. The market study also offers a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio report titled, ‘Global Pharmaceutical Contract Manufacturing Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Pharmaceutical Caps and Closures Market 2016-2020
- Global Medical Device Manufacturing Outsourcing Market 2016-2020
- Global Generic Drugs Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
